The AustralaSian COVID-19 (ASCOT) trial has known the effective peak of anticoagulant treatment needed for hospitalized patients with COVID-19, in a study published in the New England Journal of Medicine Evidence and presented at the American Society of Hematology conference.
The global COVID-19 pandemic remains a major challenge to public fitness. ASCOT researchers aim to determine which remedies are most effective in hospitalized COVID-19 patients.
Hospitalized patients with COVID-19 are at increased risk of blood clots (or thrombosis), which in turn may contribute to the progression of organ failure. Almost all of these patients will receive some degree of blood thinners.
In a foreign study, the ASCOT team conducted a randomized clinical trial for other grades of anticoagulation (or thinning of the blood) in more than 1500 patients in Australia, New Zealand, India, and Nepal.
They found that an intermediate point of anticoagulation had an 86% chance of being higher than a low dose of anticoagulation. A higher curative dose showed no benefit.
ASCOT principal investigator Professor Steven Tong, an infectious disease physician at the Royal Melbourne Hospital and co-clinical director at the Doherty Institute, said the findings will inform WHO-sponsored guidelines.
“Current practice in Australia is for low-dose anticoagulation, while foreign standards propose the maximum curative dose of anticoagulation. Therefore, our findings provide evidence that a non-unusual floor can be of maximum benefit,” Professor Tong said.
Citation attributable to Associate Professor Zoe McQuilten, Associate Director of the Transfusion Research Unit at Monash University and consultant hematologist at Monash University and Monash Health, Australia
“We are delighted that it has been decided to present it at the annual meeting of the American Society of Hematology.
“It should be noted that we found no evidence that the intermediate dose of anticoagulation produced an increased risk of bleeding. Although we found no evidence of benefit from the higher curative dose of anticoagulation, we enrolled fewer patients in this trial arm. “
Quote attributable to Professor Bala Venkatesh, George Institute for Global Health Professor, Australia
“This highlights the importance of conducting clinical trials on other fitness systems. Low and middle-income countries (LMICs) have been underrepresented in Covid-19 studies and ASCOT is one of the few studies to have a major involvement of LMIC regions The effects of the ASCOT trial are expected to have a significant influence on clinical guidelines.
Citation attributable to Dr. Susan Morpeth, clinical microbiologist and infectious disease physician at Middlemore Hospital, New Zealand
“We are pleased to be able to contribute to COVID-19 remedy trials on the ASCOT platform in Aotearoa, New Zealand. Throughout this pandemic, it has been vitally important to collect evidence from randomized clinical trials in real time to establish clinical rules. and patient management. “
Quote attributable to Professor Vivekanand Jha, Executive Director, George Institute for Global Health, India
“Although the number of cases was low in Australia and New Zealand, existing network relationships allowed us to test in India and Nepal, where COVID-19 was active, and complete this study that raises a question of global relevance. “. The rapid issue of recruitment, the complicated era of the delta wave, testifies to the commitment of the site’s researchers and the examination staff of those centers. “
The Peter Doherty Institute for Infection and Immunity
News-Medical. net – An AZoNetwork website
Owned and operated through AZoNetwork, © 2000-2022